All In Biotech

Drug Trial Radar · NCT04783090

MT1013 Clinical TRIAL In Healthy Subject

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Administration Phase 1 Clinical Trial to Evalute the Satety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamics of MT1013 Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jun 28, 2021

Primary completion

Dec 31, 2021

Study completion Mar 17, 2022

Sponsor

Sponsor type
Industry
Collaborators
WCCT Global
First posted
Mar 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single ascending dose administration phase one clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of MT1013 injection in healthy subjects.

Conditions

  • Healthy Volunteer

Interventions

  • MT1013Drug

    bispecific peptide as a CaSR agonist and a functional OGP analogue

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of MT1013 for injection in healthy adult subjects.Time frame: Three months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WCCT Global, Inc.

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.